If you're a retiree and want some dependable income, high-yielding dividend stocks can help make the most of your money. While the average stock on the S&P 500 might pay just an average of 1.2%, there are many other stocks out there that pay much higher than that -- and they aren't risky investments to hold in your portfolio.
One of the great things about the stock market is that one doesn't have to be a genius or a multimillionaire to take advantage of its wealth-building power. A person who starts out even with a relatively modest sum, like $250, then progressively (and consistently) invests more over time, and stays invested for the long term, will typically see their efforts yield significant returns -- provided they choose the right companies to buy.
It isn't easy to find steady and reliable dividend payers in the pharmaceutical industry. The key reason is simple: Drug development is a frequently laborious and expensive process that can swallow vast amounts of capital.
Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Bristol-Myers Squibb has rallied over 35% in the past 6 months, with shares approaching $60 and a price target of $70. BMY's strong dividend yield exceeds 4%, and strategic acquisitions are expected to boost future EPS and financial stability. Despite risks like patent expirations and competition, BMY's robust pipeline and R&D investments position it well for future growth.
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Bristol Myers Squibb (BMY) or Vertex Pharmaceuticals (VRTX). But which of these two stocks is more attractive to value investors?
Bristol Myers stock has witnessed a stupendous rally in the past six months. We believe there is more room for growth, and any dip in the share price can be used as a buying opportunity.
Bristol Myers (BMY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Bristol Myers Squibb has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 4.0% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of social and environmental criteria. Environmental criteria include considerations like the environmental impact of the company's products and services, as well as the company's efficiency in terms of its use of energy and resources.
Bristol-Myers Squibb Company (NYSE:BMY ) Citi's 2024 Global Healthcare Conference December 3, 2024 8:00 AM ET Company Participants Christopher Boerner - CEO and Board Chair David Elkins - EVP and CFO Conference Call Participants Geoff Meacham - Citi Mary Kate Davis - Citi Geoff Meacham Welcome to the first session of the First Annual Global Healthcare Conference at Citi. We're thrilled to be here and we're thrilled to have with us.
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.